Picture of 3M Co logo

MMM 3M Co News Story

0.000.00%
us flag iconLast trade - 00:00
IndustrialsConservativeLarge CapNeutral

RCS - 3M Company - StageZero Announces COC Protocol in Europe

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220314:nRSN6992Ea&default-theme=true

RNS Number : 6992E  3M Company  14 March 2022

StageZero Life Sciences Announces Availability of COC Protocol in Europe

TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd.
(https://pr.report/WM3v91tL) (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the
"Company"), a vertically integrated healthcare company devoted to improving
the early detection and management of cancer and other chronic diseases
through leading-edge molecular diagnostics and clinical interventions,
announces that the Care Oncology Clinic service and COC Protocol is now
available to patients living in Europe. This builds on the availability of the
service and program in the UK, the US and Canada.

Care Oncology Clinic provides high quality outpatient treatment in an
independent setting with experienced UK and European specialists. The Clinic
offers adjunctive treatments that may complement or enhance standard-of-care
cancer management. Its patented COC Protocol incorporates a multifaceted
approach, supported by peer-reviewed scientific studies, which highlight the
potential of certain treatments to target the specific energy requirements of
cancer cells, impacting their ability to grow and multiply. The addition of
non-cytotoxic agents with well-established safety profiles seeks to impede the
prospects of cancer cell survival, especially in a hostile environment, such
as during chemotherapy, radiotherapy, immunotherapy and hormone therapy.

Care is personalized for individual needs and patients receive regular
monitoring and support. The service is available both in person at premises in
Harley Street, London, UK, and remotely via telemedicine.

"Europe, with a population of approximately 750 million, and a healthcare
focus that matches our early detection and management of cancer approach, is a
natural extension to our successful Clinics in the UK. We are pleased to
continue expanding the availability of our programs geographically and this
builds upon our corporate long term growth initiatives of broadening,
deepening and expanding our offerings" said James Howard-Tripp, Chairman and
CEO of StageZero.

About StageZero Life Sciences, Ltd.

StageZero Life Sciences, Ltd. is a vertically integrated healthcare company
dedicated to improving the early detection and management of cancer and other
chronic diseases through next-generation diagnostics and unique telehealth
programs that provide clinical interventions to assist patients who currently
have cancer (COC Protocol) as well as help patients reduce the risk of
developing late-stage disease (AVRT™).

The Company's next generation test, Aristotle®, is the first ever mRNA
multi-cancer panel for simultaneously screening for multiple cancers from a
single sample of blood with high sensitivity and specificity for each cancer.
Aristotle® uses mRNA technology to identify the molecular signatures of
multiple cancer types and is built on the Company's patented technology
platform, the Sentinel Principle. This underlying technology has been
validated in more than 9,000 patients and used by more than 100,000 patients
in North America.

The Care Oncology Clinic offers a supervised treatment regimen (the COC
Protocol) for people diagnosed with cancer of any type or stage. Developed by
scientists and oncologists, the COC Protocol is intended for adjunctive
administration alongside standard-of-care cancer therapy. It is an
individualized therapeutic approach which seeks to simultaneously target
multiple metabolic cancer pathways. The aim is to restrict cancer cell energy
supply and use, which may make it more difficult overall for cancer cells to
survive, grow and adapt to changing conditions in the body. As a result, such
cells can potentially become more vulnerable to attack from cell-killing
therapies such as radiotherapy and chemotherapy. Its patented COC Protocol
incorporates a multifaceted approach, supported by peer-reviewed scientific
studies, which highlight the potential of certain treatments to target the
specific energy requirements of cancer cells, impacting their ability to grow
and multiply.

AVRT is a Physician-Led, telehealth program for identifying and managing the
early warning signs of cancer and chronic disease. Our program includes: a
comprehensive online health evaluation; blood tests to measure markers of
inflammation and metabolism; an in-depth initial physician consultation;
regular physician follow-up appointments and interval screening.

Aristotle®, as well as additional cancer diagnostics (ColonSentry®,
BreastSentry™, and the Prostate Health Index) are processed at the Company's
clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA
certified high-complexity reference laboratory in Richmond, Virginia. In
addition, the Company is also leveraging its specialty in polymerase chain
reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and
Antibody Testing (blood analysis).

StageZero Life Sciences trades on the Toronto Stock exchange under the symbol
SZLS and on the OTCQB under the symbol SZLSF.

Forward-Looking Statements

This press release contains forward-looking statements identified by words
such as "expects", "will" and similar expressions, which reflect the Company's
current expectations regarding future events. The forward-looking statements
involve risks and uncertainties that could cause the Company's actual events
to differ materially from those projected herein. Investors should consult the
Company's ongoing quarterly filings and annual reports for additional
information on risks and uncertainties relating to these forward-looking
statements. The reader is cautioned not to rely on these forward-looking
statements. The Company disclaims any obligation to update these
forward-looking statements, except as required by law.

For further information please contact:

Investor Relations

Rebecca Greco

1-855-420-7140 ext. 1838
rgreco@stagezerols.com (mailto:rgreco@stagezerols.com)

SOURCE: StageZero Life Sciences

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABKQBQBBKDOND

Recent news on 3M Co

See all news